These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32061548)

  • 1. Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile.
    Hoffman-Censits J; Choi W; Pal S; Trabulsi E; Kelly WK; Hahn NM; McConkey D; Comperat E; Matoso A; Cussenot O; Cancel-Tassin G; Fong MHY; Ross J; Madison R; Ali S
    Eur Urol Oncol; 2021 Apr; 4(2):297-300. PubMed ID: 32061548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomes.
    Burgess EF; Sanders JA; Livasy C; Symanowski J; Gatalica Z; Steuerwald NM; Arguello D; Brouwer CR; Korn WM; Grigg CM; Zhu J; Matulay JT; Clark PE; Heath EI; Raghavan D
    Urol Oncol; 2022 Aug; 40(8):383.e1-383.e10. PubMed ID: 35662501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
    Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
    Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy.
    Moussa MJ; Khandelwal J; Wilson NR; Naik SA; Subbiah V; Campbell MT; Msaouel P; Singh P; Alhalabi O
    Curr Oncol; 2024 Jun; 31(6):3342-3349. PubMed ID: 38920737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Knowledge on Genomic Profiling of Upper Tract Urothelial Carcinoma.
    De Lorenzis E; Albo G; Longo F; Bebi C; Boeri L; Montanari E
    Genes (Basel); 2021 Feb; 12(3):. PubMed ID: 33668859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small-cell carcinoma of the bladder.
    Parimi V; Choi W; Feng M; Fong M; Hoffman-Censits J; Kates M; Lombardo KA; Comperat E; McConkey DJ; Hahn NM; Esteves RS; Matoso A
    Histopathology; 2023 Jun; 82(7):991-1002. PubMed ID: 36754853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Sfakianos JP; Cha EK; Iyer G; Scott SN; Zabor EC; Shah RH; Ren Q; Bagrodia A; Kim PH; Hakimi AA; Ostrovnaya I; Ramirez R; Hanrahan AJ; Desai NB; Sun A; Pinciroli P; Rosenberg JE; Dalbagni G; Schultz N; Bajorin DF; Reuter VE; Berger MF; Bochner BH; Al-Ahmadie HA; Solit DB; Coleman JA
    Eur Urol; 2015 Dec; 68(6):970-7. PubMed ID: 26278805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
    Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
    Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
    Voutsadakis IA
    Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of molecular signatures in the urinary bladder and upper tract urothelial carcinomas: a prospective controlled clinical study.
    Dawood EE; Awadalla A; Hashem A; Shokeir AA; Abdel-Aziz AF
    J Egypt Natl Canc Inst; 2022 Nov; 34(1):47. PubMed ID: 36372809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.
    Koshkin VS; Garcia JA; Reynolds J; Elson P; Magi-Galluzzi C; McKenney JK; Isse K; Bishop E; Saunders LR; Balyimez A; Rashid S; Hu M; Stephenson AJ; Fergany AF; Lee BH; Haber GP; Dowlati A; Gilligan T; Ornstein MC; Rini BI; Abazeed ME; Mian OY; Grivas P
    Clin Cancer Res; 2019 Jan; 25(1):210-221. PubMed ID: 30327311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2.
    Posada JM; Yakirevich E; Kamat AM; Sood A; Jacob JM; Bratslavsky G; Grivas P; Spiess PE; Li R; Necchi A; Mega AE; Golijanin DJ; Pavlick D; Huang RSP; Lin D; Danziger N; Sokol ES; Sivakumar S; Ross JS; Cheng L
    Mod Pathol; 2024 Mar; 37(3):100424. PubMed ID: 38219954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
    Nassar AH; Umeton R; Kim J; Lundgren K; Harshman L; Van Allen EM; Preston M; Dong F; Bellmunt J; Mouw KW; Choueiri TK; Sonpavde G; Kwiatkowski DJ
    Clin Cancer Res; 2019 Apr; 25(8):2458-2470. PubMed ID: 30593515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
    Yang K; Yu W; Liu H; Ding F; Zhang Y; Zhang Y; Wang W; Lou F; Cao S; Wang H; He Z
    Oncologist; 2021 Aug; 26(8):e1395-e1405. PubMed ID: 34050578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in genomic profile of high-grade urothelial carcinoma according to tumor location.
    Park CK; Cho NH
    Urol Oncol; 2022 Mar; 40(3):109.e1-109.e9. PubMed ID: 34663543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis.
    Chang MT; Penson A; Desai NB; Socci ND; Shen R; Seshan VE; Kundra R; Abeshouse A; Viale A; Cha EK; Hao X; Reuter VE; Rudin CM; Bochner BH; Rosenberg JE; Bajorin DF; Schultz N; Berger MF; Iyer G; Solit DB; Al-Ahmadie HA; Taylor BS
    Clin Cancer Res; 2018 Apr; 24(8):1965-1973. PubMed ID: 29180607
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma.
    Sjödahl G; Eriksson P; Patschan O; Marzouka NA; Jakobsson L; Bernardo C; Lövgren K; Chebil G; Zwarthoff E; Liedberg F; Höglund M
    Int J Cancer; 2020 May; 146(9):2636-2647. PubMed ID: 31609466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.